Rongcan Biomedical Technology

Rongcan Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of mRNA-based therapeutics and vaccines. The company has developed a proprietary lipid nanoparticle (LNP) delivery platform, featuring a library of novel ionizable lipids designed to optimize the delivery of nucleic acid cargos. Its pipeline includes candidates for infectious diseases, such as COVID-19 and RSV, as well as programs in oncology and rare genetic disorders. Rongcan maintains integrated capabilities spanning mRNA sequence design, LNP formulation, and GMP-compliant manufacturing. The company is backed by leading venture capital firms, including Sequoia China and GL Ventures, to advance its mission of providing innovative genetic medicines.